Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:AXSM NASDAQ:NUVL NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.61-1.0%$5.37$3.21▼$7.18$1.61B0.743.23 million shs2.35 million shsAXSMAxsome Therapeutics$118.42-3.7%$112.20$75.56▼$139.13$6.14B0.54563,318 shs700,752 shsNUVLNuvalent$80.47-2.1%$78.68$55.53▼$113.51$5.93B1.29391,814 shs405,266 shsTGTXTG Therapeutics$32.16-0.9%$32.38$21.16▼$46.48$5.15B1.881.95 million shs2.39 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.05%+1.38%+14.96%+83.61%+10.91%AXSMAxsome Therapeutics-3.69%-5.39%+8.25%+13.76%+30.09%NUVLNuvalent-2.13%-0.52%+2.85%+2.85%-6.03%TGTXTG Therapeutics-0.92%-0.16%+15.39%-10.69%+39.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.61-1.0%$5.37$3.21▼$7.18$1.61B0.743.23 million shs2.35 million shsAXSMAxsome Therapeutics$118.42-3.7%$112.20$75.56▼$139.13$6.14B0.54563,318 shs700,752 shsNUVLNuvalent$80.47-2.1%$78.68$55.53▼$113.51$5.93B1.29391,814 shs405,266 shsTGTXTG Therapeutics$32.16-0.9%$32.38$21.16▼$46.48$5.15B1.881.95 million shs2.39 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.05%+1.38%+14.96%+83.61%+10.91%AXSMAxsome Therapeutics-3.69%-5.39%+8.25%+13.76%+30.09%NUVLNuvalent-2.13%-0.52%+2.85%+2.85%-6.03%TGTXTG Therapeutics-0.92%-0.16%+15.39%-10.69%+39.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.10Buy$11.7077.00% UpsideAXSMAxsome Therapeutics 3.13Buy$177.8650.19% UpsideNUVLNuvalent 3.08Buy$120.9150.25% UpsideTGTXTG Therapeutics 2.75Moderate Buy$46.2543.81% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, AXSM, NUVL, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$115.009/4/2025NUVLNuvalentGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$122.009/3/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$14.009/3/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$163.009/2/2025NUVLNuvalentRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$105.009/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy8/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$112.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$8.00 ➝ $9.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.008/5/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00 ➝ $12.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M4.77N/AN/A$0.73 per share9.05AXSMAxsome Therapeutics$495.03M11.94N/AN/A$1.18 per share100.36NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ATGTXTG Therapeutics$454.07M11.24$0.12 per share270.58$1.43 per share22.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A21.32N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.07N/A41.99N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3786.9232.16N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest ARDX, AXSM, NUVL, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03AXSMAxsome Therapeutics1.661.571.51NUVLNuvalentN/A13.5713.57TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%AXSMAxsome Therapeutics81.49%NUVLNuvalent97.26%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%AXSMAxsome Therapeutics22.30%NUVLNuvalent10.20%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableARDX, AXSM, NUVL, and TGTX HeadlinesRecent News About These CompaniesInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of Stock2 hours ago | insidertrades.comWoodline Partners LP Takes $21.02 Million Position in TG Therapeutics, Inc. $TGTX4 hours ago | marketbeat.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingSeptember 10 at 7:30 AM | globenewswire.comTG Therapeutics Begins Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI in Patients with Relapsing Multiple SclerosisSeptember 8, 2025 | quiverquant.comQTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced EnrollmentSeptember 8, 2025 | globenewswire.comCinctive Capital Management LP Purchases Shares of 14,145 TG Therapeutics, Inc. $TGTXSeptember 8, 2025 | marketbeat.comWhy TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback ProgramSeptember 7, 2025 | finance.yahoo.comBanque Transatlantique SA Invests $610,000 in TG Therapeutics, Inc. $TGTXSeptember 6, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Gap Up - Still a Buy?September 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.com683 Capital Management LLC Reduces Holdings in TG Therapeutics, Inc. $TGTXSeptember 4, 2025 | marketbeat.comTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comWhy Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?September 3, 2025 | zacks.comTG Therapeutics completes share repurchase program, authorize new $100M programSeptember 3, 2025 | msn.comTG Therapeutics Board Authorizes New $100M Share Repurchase ProgramSeptember 3, 2025 | msn.comTG Therapeutics Completes $100 Million Share Repurchase Program and Authorizes New $100 Million Repurchase InitiativeSeptember 3, 2025 | quiverquant.comQTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million ProgramSeptember 3, 2025 | globenewswire.comDriehaus Capital Management LLC Takes $30.55 Million Position in TG Therapeutics, Inc. $TGTXSeptember 1, 2025 | marketbeat.comRafferty Asset Management LLC Has $7.17 Million Holdings in TG Therapeutics, Inc. $TGTXAugust 30, 2025 | marketbeat.comJump Financial LLC Buys New Shares in TG Therapeutics, Inc. $TGTXAugust 30, 2025 | marketbeat.comTG Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, AXSM, NUVL, and TGTX Company DescriptionsArdelyx NASDAQ:ARDX$6.61 -0.07 (-1.05%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.62 +0.00 (+0.08%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Axsome Therapeutics NASDAQ:AXSM$118.42 -4.54 (-3.69%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$118.38 -0.05 (-0.04%) As of 09/12/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Nuvalent NASDAQ:NUVL$80.47 -1.75 (-2.13%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$80.50 +0.03 (+0.04%) As of 09/12/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$32.16 -0.30 (-0.92%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$32.11 -0.05 (-0.16%) As of 09/12/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
